MYND-604 / MYND Life Sci - LARVOL DELTA

MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs (PRNewswire) - "MYND Life Sciences...is pleased to announce it has filed additional provisional patents that utilize various psilocybin analogs to target clinical depression....The patent application addresses methods of inhibiting neuroinflammation to potentially treat a wide variety of neuropsychiatric disorders, including but not limited to; Major Depressive Disorder, schizophrenia, anxiety, bipolar disorder, obsessive-compulsive disorder (OCD), and posttraumatic stress disorder (PTSD), among others....MYND-604 is the lead candidate being developed as a novel oral dosage to treat MDD and brings much needed innovation to the Selective Serotonin Reuptake Inhibitor ('SSRI') market."

Patent • CNS Disorders • Depression • Major Depressive Disorder